Share This Author
White matter changes caused by chronic solvent abuse.
There are some patients with restricted but severe enough change to cause the neurologic symptoms in specific regions, such as the brain stem and/or cerebellum, before the brain atrophy becomes apparent, which suggests that the restricted white matter change represents not only an early change of diffuseWhite matter change, but at least in some cases also represents a qualitatively different change than that of diffusewhite matter change.
Abnormal cerebral perfusion in chronic methamphetamine abusers: A study using 99mTC-HMPAO and spect
Effects of MRI abnormalities on WAIS‐R performance in solvent abusers
The data indicate that solvent abuse causes the decline in the test performance reflecting cognitive and fine motor dysfunction and that white matter changes and pontine atrophy may have some roles in this decline.
Regional cerebral blood flow abnormalities in chronic solvent abusers
- S. Okada, N. Yamanouchi, Toshio Sato
- Medicine, PsychologyPsychiatry and clinical neurosciences
- 1 June 1999
It is suggested that rCBF abnormalities, especially in the prefrontal cortex, develop in chronic solvent abusers, and that this frontal hypoperfusion may be a biological basis of amotivational syndrome.
Symptomatological structure of volatile solvent-induced psychosis: is "solvent psychosis" a discernible syndrome?
- K. Wada, Kazuhiro Nakayama, S. Iwashita
- Psychology, MedicineNihon Arukoru Yakubutsu Igakkai zasshi = Japanese…
- 1 October 2005
Clinical observations the "amotivational syndrome" may be a characteristic feature of patients suffering from solvent-induced psychosis and suggest "solvent psychosis" is a discernible syndrome, and is distinctive from psychotic symptoms of typical schizophrenia.
T2 relaxometry in the central nervous system of solvent misusers
Results confirmed T2 prolongation in the white matter with T2 shortening in the thalamus of solvent misusers with white matter changes, and provided further support for the classification ofwhite matter changes.
[Clinical equivalence trial of UROCALUN miniaturized tablet in patients with upper urinary tract stone disease].
- Y. Higashi, H. Yamada, Go Kobori, S. Hirai, J. Kawamura, Yuusaku Okada
- MedicineHinyokika kiyo. Acta urologica Japonica
- 1 March 2005
It is suggested that the miniaturized tablet contributes to improve the medication compliance for patients and thus it is expected to improved the clinical efficacy of UROCALUN.
Impact of the COVID-19 pandemic on patients with mental health problems and the differences among diagnostic categories
- Y. Mashima, T. Koizumi, A. Koreki
- Medicine, PsychologyThe International journal of social psychiatry
- 2 June 2022
One third of patients reported symptom deterioration during the COVID-19 pandemic, which was associated with stress and daily life changes, and patients with good adaptability to environmental changes might resilient against symptom deterioration.
[Basic policy towards patient's violation of drug control law].
- S. Hirai
- Law, MedicineNihon rinsho. Japanese journal of clinical…
- 1 December 2003
Medical workers should avoid prosecuting a patient for illegal drug use, so that drug users can seek help and try to put the patient in a situation where the patient's drug use in the future can be treated by the criminal justice system.
[Drug therapy of Alzheimer's disease. Problems of the criteria of clinical trials of nootropic drugs].
- S. Hirai
- MedicineNihon rinsho. Japanese journal of clinical…
- 1 July 1988